{
  "patient_id": "MDT2024001",
  "summary": "MDT analysis completed",
  "ehr_analysis": {
    "summary": "A full performance status assessment (e.g., using the Eastern Cooperative Oncology Group (ECOG) performance status scale) is needed. Based on the reported symptoms (fatigue, weight loss, decreased appetite), a preliminary ECOG performance status of 2 or 3 is suspected, but this needs formal evaluation.  This will significantly influence treatment planning.",
    "details": {
      "summary": "A full performance status assessment (e.g., using the Eastern Cooperative Oncology Group (ECOG) performance status scale) is needed. Based on the reported symptoms (fatigue, weight loss, decreased appetite), a preliminary ECOG performance status of 2 or 3 is suspected, but this needs formal evaluation.  This will significantly influence treatment planning.",
      "key_history_points": [],
      "current_presentation": {
        "main_symptoms": [],
        "performance_status": "**  Treatment will depend on the histopathological diagnosis, staging, and performance status.  Options may include surgery, chemotherapy, radiotherapy, or a combination thereof.  Palliative care will also be an important consideration throughout the treatment process.",
        "comorbidity_impact": "**  The patient's comorbidities (diabetes, hypertension, osteoarthritis) will need to be managed concurrently with any cancer treatment.  Careful consideration of drug interactions between anti-cancer medications and her current medications (Metformin, Lisinopril, PRN NSAIDs) is crucial."
      },
      "risk_factors": [],
      "clinical_implications": [],
      "raw_output": "**EHR Analysis Agent Report - Patient ID: MDT2024001**\n\n**1. Key History Points:**\n\n* **Chronological Progression of Symptoms:**  The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15, 2024) initially characterized as moderate to severe, progressing to include blood-tinged sputum.  Concomitant symptoms include unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats. This constellation of symptoms warrants serious investigation, strongly suggesting a possible malignancy.\n\n* **Medical History:** The patient has a history of well-controlled Type 2 Diabetes Mellitus (since 2015), well-controlled hypertension (since 2016), and osteoarthritis (since 2018).  These comorbidities will need to be carefully considered during treatment planning.  Her smoking history (former smoker, quit 10 years ago) represents a significant risk factor for lung cancer.\n\n* **Social and Functional Factors:** The patient is retired, suggesting a potentially reduced ability to tolerate intensive treatment regimens compared to an actively employed individual.  However, further assessment is required to fully understand her functional capacity and support systems.\n\n**2. Current Clinical Status:**\n\n* **Primary Complaint:** Persistent cough with hemoptysis.\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe, suggestive of a possible pulmonary mass or consolidation, and right supraclavicular lymphadenopathy, a concerning sign often associated with metastatic disease.\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, WBC, and platelet counts, which, while not definitively excluding malignancy, does not reveal overt signs of severe anemia or infection.  Liver function tests (LFTs) are mildly elevated (ALT 28 U/L, AST 32 U/L), which could be related to underlying conditions or a paraneoplastic syndrome.  Further investigation is required.  Albumin is within the normal range.\n\n**3. Relevant Risk Factors:**\n\n* **Age:** 62 years old (increased risk for various malignancies).\n* **Gender:** Female (lung cancer is more common in males, but this patient's symptoms are concerning).\n* **Smoking History:** Former smoker (significant risk factor for lung cancer).\n* **Symptoms:** Persistent cough with hemoptysis, weight loss, fatigue, decreased appetite, and night sweats (highly suggestive of malignancy).\n* **Physical Exam Findings:** Decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy (strongly suggestive of lung cancer with potential metastasis).\n\n**4. Performance Status Assessment:**\n\nA full performance status assessment (e.g., using the Eastern Cooperative Oncology Group (ECOG) performance status scale) is needed. Based on the reported symptoms (fatigue, weight loss, decreased appetite), a preliminary ECOG performance status of 2 or 3 is suspected, but this needs formal evaluation.  This will significantly influence treatment planning.\n\n\n**5. Clinical Implications:**\n\nThe clinical picture strongly suggests the possibility of lung cancer.  The right supraclavicular lymphadenopathy raises concern for metastatic disease.  Further investigations are urgently required, including:\n\n* **Imaging:**  High-resolution computed tomography (HRCT) of the chest is essential to characterize the pulmonary lesion and assess for mediastinal and distant metastases.  Further imaging (e.g., CT abdomen/pelvis) may be indicated based on the HRCT findings.\n* **Bronchoscopy with Bronchoalveolar Lavage (BAL):**  This procedure is crucial for obtaining tissue samples for histopathological examination and cytology, allowing for definitive diagnosis and subtyping of the cancer.\n* **Biopsy of the supraclavicular lymph node:**  If the lymphadenopathy is confirmed, biopsy is crucial to determine if it is metastatic.\n* **Further laboratory investigations:**  Consideration should be given to serum tumor markers (e.g., CEA, CYFRA 21-1) and potentially further blood tests to further investigate the mildly elevated LFTs.\n\n**Comorbidity Management:**  The patient's comorbidities (diabetes, hypertension, osteoarthritis) will need to be managed concurrently with any cancer treatment.  Careful consideration of drug interactions between anti-cancer medications and her current medications (Metformin, Lisinopril, PRN NSAIDs) is crucial.\n\n**Treatment Planning:**  Treatment will depend on the histopathological diagnosis, staging, and performance status.  Options may include surgery, chemotherapy, radiotherapy, or a combination thereof.  Palliative care will also be an important consideration throughout the treatment process.\n\n**Limitations and Uncertainties:**  This analysis is based on the limited information provided.  A definitive diagnosis and comprehensive treatment plan can only be formulated after completion of the recommended investigations.\n\n\n**Conclusion:** This patient requires urgent further investigation to confirm the suspected diagnosis of lung cancer and determine the extent of disease.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, and pathologists is essential for optimal management.  Patient preferences and values should be central to all treatment decisions."
    }
  },
  "imaging_analysis": {
    "summary": "**Imaging Analysis Report - Patient ID: MDT2024001**",
    "details": {
      "summary": "**Imaging Analysis Report - Patient ID: MDT2024001**",
      "disease_extent": "Primary Tumor: ** 12.4 (PET-CT). Nodal Status: **  While the PET-CT is usually considered adequate for distant metastasis assessment, the concerning supraclavicular lymphadenopathy warrants further investigation.  A CT of the neck and upper mediastinum may be valuable to assess for additional nodal involvement.  If supraclavicular lymph node biopsy confirms metastasis, the need for further imaging is reduced.. Metastatic Status: .",
      "staging": "Clinical Stage: . Key Findings: * **Chest X-Ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  This initial imaging served as a screening tool and prompted further investigation.; * **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, characteristic of malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.; * **PET-CT (2024-02-12):**  The right upper lobe mass demonstrates an SUVmax of 12.4, consistent with high metabolic activity characteristic of malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, indicating significant metabolic activity suggestive of nodal involvement.  No evidence of distant metastatic disease is observed.; * **Primary Lesion:** 3.8 x 3.2 cm (CT Chest); Based on the available imaging studies, the patient presents with a large primary lung mass in the right upper lobe with involvement of regional lymph nodes (hilar and mediastinal).  There is no evidence of distant metastases on the performed imaging.  This strongly suggests a Stage IIIA Non-Small Cell Lung Cancer (NSCLC) according to the 8th edition TNM staging system.  However, definitive staging requires histopathological confirmation of the diagnosis and further assessment of lymph node involvement.  The exact T stage will depend on further pathological assessment, and the N stage requires more precise characterisation of lymph node involvement which may require additional imaging or mediastinoscopy.; The primary lesion is located in the right upper lobe, close to the hilum, explaining the associated hilar lymphadenopathy.  The presence of right supraclavicular lymphadenopathy on physical exam, while not directly visualized on the current imaging, raises concern for potential N3 disease. This necessitates further investigation.  The mild emphysematous changes may influence surgical resectability.",
      "treatment_implications": [],
      "disease_extent_formatted": "Primary Tumor: ** 12.4 (PET-CT). Nodal Status: **  While the PET-CT is usually considered adequate for distant metastasis assessment, the concerning supraclavicular lymphadenopathy warrants further investigation.  A CT of the neck and upper mediastinum may be valuable to assess for additional nodal involvement.  If supraclavicular lymph node biopsy confirms metastasis, the need for further imaging is reduced.. Metastatic Status: .",
      "staging_formatted": "Clinical Stage: . Key Findings: * **Chest X-Ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  This initial imaging served as a screening tool and prompted further investigation.; * **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, characteristic of malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.; * **PET-CT (2024-02-12):**  The right upper lobe mass demonstrates an SUVmax of 12.4, consistent with high metabolic activity characteristic of malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, indicating significant metabolic activity suggestive of nodal involvement.  No evidence of distant metastatic disease is observed.; * **Primary Lesion:** 3.8 x 3.2 cm (CT Chest); Based on the available imaging studies, the patient presents with a large primary lung mass in the right upper lobe with involvement of regional lymph nodes (hilar and mediastinal).  There is no evidence of distant metastases on the performed imaging.  This strongly suggests a Stage IIIA Non-Small Cell Lung Cancer (NSCLC) according to the 8th edition TNM staging system.  However, definitive staging requires histopathological confirmation of the diagnosis and further assessment of lymph node involvement.  The exact T stage will depend on further pathological assessment, and the N stage requires more precise characterisation of lymph node involvement which may require additional imaging or mediastinoscopy.; The primary lesion is located in the right upper lobe, close to the hilum, explaining the associated hilar lymphadenopathy.  The presence of right supraclavicular lymphadenopathy on physical exam, while not directly visualized on the current imaging, raises concern for potential N3 disease. This necessitates further investigation.  The mild emphysematous changes may influence surgical resectability."
    }
  },
  "pathology_analysis": {
    "summary": "**",
    "details": {
      "summary": "**",
      "histology": "**",
      "molecular_profile": "Key Mutations: Key mutations not specified. Immunotherapy Markers: **  While PD-L1 expression is high, additional biomarker testing might be considered depending on treatment decisions.  This could include testing for other relevant biomarkers that might guide treatment choices.",
      "therapeutic_implications": [
        "The provided data does not specify the grade and differentiation of the adenocarcinoma.  Further pathological assessment of the biopsy specimen, including review by a specialist lung pathologist, is necessary to determine the grade (e.g., well-differentiated, moderately differentiated, poorly differentiated) and assess the degree of differentiation. This information is crucial for prognostication and treatment planning.",
        "Molecular testing reveals a *KRAS* G12C mutation.  *EGFR*, *ALK*, and *ROS1* are all wild-type (negative for rearrangements).  The presence of a *KRAS* G12C mutation is a significant finding, as it indicates a specific molecular subtype of lung adenocarcinoma with implications for targeted therapy.",
        "PD-L1 expression is 80%, indicating a high level of PD-L1 expression.  This high expression suggests potential responsiveness to immunotherapy, specifically PD-1/PD-L1 inhibitors.  However, the precise clinical significance of PD-L1 expression needs to be considered in the context of the patient\u2019s overall clinical presentation and other factors influencing treatment decisions.",
        "**5. Therapeutic Targets:**",
        "* **KRAS G12C Mutation:** The presence of a *KRAS* G12C mutation makes this patient a candidate for treatment with a KRAS G12C inhibitor (e.g., sotorasib or adagrasib).  These targeted therapies have demonstrated efficacy in this specific molecular subtype of lung adenocarcinoma.",
        "* **High PD-L1 Expression:** The high PD-L1 expression (80%) suggests that immunotherapy with PD-1/PD-L1 inhibitors (e.g., pembrolizumab, nivolumab) could be a beneficial treatment option, either as monotherapy or in combination with chemotherapy or targeted therapy. The high PD-L1 expression could also be considered in the context of adjuvant immunotherapy post-surgery if resection is feasible.",
        "* **Combination Therapy:**  Given the high PD-L1 expression and the *KRAS* G12C mutation, combination therapy might be considered.  This could involve a KRAS G12C inhibitor combined with immunotherapy or chemotherapy.  The optimal combination regimen will depend on the patient's overall clinical status, performance status, and other factors.",
        "1. **Complete pathological assessment:**  Detailed review of the biopsy specimen by an expert lung pathologist to determine the grade and differentiation of the adenocarcinoma.  This will significantly impact prognosis and treatment selection.",
        "3. **Further biomarker testing:**  While PD-L1 expression is high, additional biomarker testing might be considered depending on treatment decisions.  This could include testing for other relevant biomarkers that might guide treatment choices.",
        "4. **ECOG performance status assessment:**  A formal assessment of the patient's performance status is critical to guide treatment decisions and ensure appropriate patient selection for different treatment modalities.",
        "This patient has a lung adenocarcinoma with a *KRAS* G12C mutation and high PD-L1 expression. This profile suggests several therapeutic options, including KRAS G12C inhibitors and immunotherapy.  The optimal treatment strategy will depend on the results of further staging investigations, the determination of tumor grade and differentiation, and the patient's performance status.  A multidisciplinary team (MDT) approach, involving oncologists, thoracic surgeons, pulmonologists, radiologists, and pathologists, is essential to develop a personalized and evidence-based treatment plan that maximizes the patient's chances of a positive outcome while taking into account her comorbidities and overall health.  The patient's preference and values should be central to this process.  Palliative care should also be considered from the outset to manage symptoms and improve quality of life."
      ],
      "molecular_profile_formatted": "Key Mutations: Key mutations not specified. Immunotherapy Markers: **  While PD-L1 expression is high, additional biomarker testing might be considered depending on treatment decisions.  This could include testing for other relevant biomarkers that might guide treatment choices."
    }
  },
  "guideline_recommendations": [
    {
      "guideline": "**",
      "version": "",
      "category": "",
      "recommendations": [
        "*3. Special Populations and Considerations:**",
        "*4. Evidence Levels:**",
        "The evidence levels for treatment recommendations will vary depending on the specific treatment modality and the patient's characteristics.  However, the following is generally true:",
        "**KRAS G12C inhibitors:**  High-level evidence supports the use of KRAS G12C inhibitors (sotorasib or adagrasib) in patients with *KRAS* G12C-mutated NSCLC.",
        "**Immunotherapy (PD-1/PD-L1 inhibitors):**  High-level evidence supports the use of immunotherapy in patients with high PD-L1 expression NSCLC.  The optimal approach (monotherapy or combination) depends on the specific context.",
        "**Chemotherapy:**  Evidence supporting chemotherapy varies depending on stage and other factors.  It may be used alone or in combination with other therapies.",
        "**Surgery:**  Surgical resection is a possibility if the tumor is resectable and the patient's performance status allows it, potentially followed by adjuvant therapies.",
        "*5. Clinical Trial Eligibility:**",
        "*Recommendations:**",
        "**Complete Staging:**  Urgent completion of staging investigations is crucial to precisely define the extent of the disease. This includes:",
        "Biopsy of the supraclavicular lymph node to confirm or refute N3 disease.",
        "Further imaging (CT neck and upper mediastinum) if supraclavicular lymph node biopsy is positive.",
        "Formal ECOG performance status assessment.",
        "**Treatment Options:**  Based on the current data (subject to change after complete staging):",
        "**KRAS G12C inhibitor (sotorasib or adagrasib):**  This is a strong candidate given the *KRAS* G12C mutation.",
        "**Immunotherapy (PD-1/PD-L1 inhibitor):**  This is also a strong candidate given the high PD-L1 expression (80%).  Combination with a KRAS G12C inhibitor should be considered.",
        "**Chemotherapy:**  May be considered as part of a combination regimen or as a single agent depending on the final staging and performance status.",
        "**Surgery (if feasible):**  Surgical resection, followed by adjuvant therapy, may be an option if the tumor is resectable and the patient's performance status allows it.  The presence of emphysema may limit resectability.",
        "**Clinical Trial Consideration:**  Actively search for relevant clinical trials evaluating combinations of KRAS G12C inhibitors and immunotherapy for advanced NSCLC.",
        "**Special Considerations:**  Close monitoring of comorbidities (diabetes, hypertension, osteoarthritis) is crucial.  Careful medication management is necessary to minimize drug interactions and adverse events.  A comprehensive palliative care plan should be established to manage symptoms and improve quality of life."
      ]
    },
    {
      "guideline": "** Any deviations from standard practice (e.g., choosing a specific treatment regimen over another) will be thoroughly documented in the patient's medical record, including rationale and justifications based on the patient's unique characteristics and the latest evidence-based guidelines.  The patient's preferences and values should be central to all decisions.",
      "version": "",
      "category": "",
      "recommendations": [
        "*Limitations:**  This analysis is based on the information provided.  The recommendations are preliminary and are subject to change based on the results of the further investigations and the MDT discussion.  A definitive diagnosis and treatment plan can only be formulated after a complete evaluation by a multidisciplinary team."
      ]
    }
  ],
  "specialist_assessment": {
    "summary": "**",
    "details": {
      "overall_assessment": "**",
      "treatment_considerations": [
        "This 62-year-old female presents with a highly suggestive clinical picture of advanced Non-Small Cell Lung Cancer (NSCLC), likely adenocarcinoma, based on the imaging findings (large right upper lobe mass with hilar and mediastinal lymphadenopathy, SUVmax 12.4 on PET-CT), physical examination (right supraclavicular lymphadenopathy, decreased breath sounds in the right upper lobe), and constitutional symptoms (cough with hemoptysis, weight loss, fatigue, anorexia, night sweats).  The preliminary staging suggests at least Stage IIIA disease, but this requires confirmation through biopsy and further staging investigations.  The presence of a *KRAS* G12C mutation and high PD-L1 expression (80%) significantly impacts treatment options.  Her comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) require careful consideration in treatment planning and necessitate close monitoring.  A formal ECOG performance status assessment is urgently needed to guide treatment decisions and assess her ability to tolerate different therapies.",
        "**4. Treatment Options:**",
        "* **Immunotherapy (Pembrolizumab or Nivolumab):**  The high PD-L1 expression strongly suggests potential benefit from immunotherapy, either as monotherapy or in combination with a KRAS G12C inhibitor.",
        "* **Chemotherapy:**  May be considered as part of a combination regimen (e.g., with immunotherapy or a KRAS G12C inhibitor) or as a single agent, particularly if the patient is not a candidate for targeted therapy or immunotherapy due to performance status or other factors.",
        "* **Surgery:**  Surgical resection might be considered *if* further investigations confirm resectable disease and the patient's performance status allows it.  The presence of emphysema and the size of the tumor may limit resectability.  Adjuvant therapy would likely be indicated post-surgery."
      ],
      "risk_assessment": "**",
      "proposed_approach": "**7. Treatment Recommendations:**",
      "follow_up_recommendations": [
        "*11. Limitations and Uncertainties:**",
        "This assessment is based on the available data.  The final diagnosis and treatment plan will be determined after completion of the recommended investigations and discussion within a multidisciplinary team (MDT).  The patient\u2019s preferences and values should be central to all decisions."
      ]
    }
  },
  "treatment_options": [
    {
      "option": "**7. Treatment Recommendations:**",
      "source": "Specialist Assessment"
    },
    {
      "option": "This 62-year-old female presents with a highly suggestive clinical picture of advanced Non-Small Cell Lung Cancer (NSCLC), likely adenocarcinoma, based on the imaging findings (large right upper lobe mass with hilar and mediastinal lymphadenopathy, SUVmax 12.4 on PET-CT), physical examination (right supraclavicular lymphadenopathy, decreased breath sounds in the right upper lobe), and constitutional symptoms (cough with hemoptysis, weight loss, fatigue, anorexia, night sweats).  The preliminary staging suggests at least Stage IIIA disease, but this requires confirmation through biopsy and further staging investigations.  The presence of a *KRAS* G12C mutation and high PD-L1 expression (80%) significantly impacts treatment options.  Her comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) require careful consideration in treatment planning and necessitate close monitoring.  A formal ECOG performance status assessment is urgently needed to guide treatment decisions and assess her ability to tolerate different therapies.",
      "source": "Specialist Assessment"
    },
    {
      "option": "**4. Treatment Options:**",
      "source": "Specialist Assessment"
    },
    {
      "option": "* **Immunotherapy (Pembrolizumab or Nivolumab):**  The high PD-L1 expression strongly suggests potential benefit from immunotherapy, either as monotherapy or in combination with a KRAS G12C inhibitor.",
      "source": "Specialist Assessment"
    },
    {
      "option": "* **Chemotherapy:**  May be considered as part of a combination regimen (e.g., with immunotherapy or a KRAS G12C inhibitor) or as a single agent, particularly if the patient is not a candidate for targeted therapy or immunotherapy due to performance status or other factors.",
      "source": "Specialist Assessment"
    },
    {
      "option": "* **Surgery:**  Surgical resection might be considered *if* further investigations confirm resectable disease and the patient's performance status allows it.  The presence of emphysema and the size of the tumor may limit resectability.  Adjuvant therapy would likely be indicated post-surgery.",
      "source": "Specialist Assessment"
    }
  ],
  "evaluation_score": 0.0,
  "evaluation_comments": "## MDT Report Evaluation: Patient ID MDT2024001\n\n**Overall Quality Score:** 0.75\n\n**Evaluation based on provided criteria:**\n\n**1. Completeness of Assessment:** 0.8\n\n**Strengths:** The report comprehe...",
  "evaluation_formatted": "Overall Score: 0.00\n\nKey Strengths:\n- This MDT report demonstrates a reasonable attempt at a comprehensive assessment, but significant improvements are needed to meet the standard of a high-quality, evidence-based, and patient-centered report.  The numerous incomplete sections and lack of crucial details (e.g., complete medication list, ECOG performance status, detailed discussion of palliative care, patient preferences, clear timeline for investigations and follow-up) are major weaknesses.  The report needs substantial revision before it can be considered complete and ready for implementation.  Addressing the areas for improvement and missing elements listed above is crucial.  A revised report should include specific guideline references, a more detailed discussion of treatment options and their rationale, and a clear plan for shared decision-making with the patient.\n\nAreas for Improvement:\n- **3. Patient-Centered Focus:** 0.7\n- **4. Logical Consistency:** 0.9\n- **5. Documentation Quality:** 0.7",
  "markdown_summary": "# MDT Summary: MDT2024001\n\n## Diagnosis & Staging\n- **Confirmed Diagnosis**: Suspected advanced Non-Small Cell Lung Cancer (NSCLC), likely adenocarcinoma.  Requires tissue confirmation.\n- **Stage**: Suspected Stage IIIA (based on imaging), requires confirmation.\n- **Key Molecular Findings**: *KRAS* G12C mutation; PD-L1 expression 80%.\n- **Performance Status**: Requires formal ECOG performance status assessment; preliminary suspicion of ECOG 2 or 3.\n\n## Key Recommendations\n1.  Urgent completion of staging investigations including supraclavicular lymph node biopsy and further imaging if indicated.\n2.  Consideration of KRAS G12C inhibitor (sotorasib or adagrasib) and/or immunotherapy (PD-1/PD-L1 inhibitor) based on final staging and performance status.  Combination therapy may be appropriate.\n3.  Surgical resection if deemed feasible after complete staging and assessment of performance status, followed by adjuvant therapy.\n\n\n## Critical Next Steps\n- [ ] Formal ECOG performance status assessment.\n- [ ] Biopsy of supraclavicular lymph node.\n- [ ] Further imaging (CT neck and upper mediastinum) if supraclavicular lymph node biopsy is positive.\n\n**Note:** This summary is based on preliminary findings.  Definitive diagnosis and treatment plan will be determined after completion of recommended investigations and MDT discussion.  Patient preferences and values will be central to all decisions.  Palliative care should be considered.",
  "timestamp": "2025-04-26T14:13:18.491317"
}